Ballal Rahul D.
Insider CIK 1805097 · AGIO Director · IMRA Chief Executive Officer, Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| AGIO AGIOS PHARMACEUTICALS, INC | A Award deriv | 2026-06-18 | 2026-06-23 | 14,950 | — | $0 | 14,950 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | A Award deriv | 2026-06-18 | 2026-06-23 | 2,927 | — | $0 | 2,927 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | M Exercise deriv | 2026-06-18 | 2026-06-23 | 2,816 | — | $0 | 0 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | M Exercise | 2026-06-18 | 2026-06-23 | 2,816 | — | $0 | 15,230 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | A Award deriv | 2026-02-12 | 2026-02-17 | 17,126 | — | $0 | 17,126 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | M Exercise deriv | 2025-08-11 | 2025-08-13 | 2,302 | — | $0 | 0 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | M Exercise | 2025-08-11 | 2025-08-13 | 2,302 | — | $0 | 12,414 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | M Exercise deriv | 2025-06-20 | 2025-06-23 | 2,120 | — | $0 | 0 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | M Exercise | 2025-06-20 | 2025-06-23 | 2,120 | — | $0 | 10,112 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | A Award deriv | 2025-06-18 | 2025-06-23 | 15,768 | — | $0 | 15,768 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | A Award deriv | 2025-06-18 | 2025-06-23 | 2,816 | — | $0 | 2,816 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | A Award deriv | 2025-02-06 | 2025-02-10 | 20,491 | — | $0 | 20,491 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | M Exercise deriv | 2024-11-08 | 2024-11-12 | 10,000 | — | $0 | 17,947 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | S Sale | 2024-11-08 | 2024-11-12 | 1,500 | $59.21 | $88.8K | 7,992 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | S Sale | 2024-11-08 | 2024-11-12 | 4,929 | $58.57 | $288.7K | 9,492 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | S Sale | 2024-11-08 | 2024-11-12 | 3,571 | $57.24 | $204.4K | 14,421 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | M Exercise | 2024-11-08 | 2024-11-12 | 10,000 | $25.99 | $259.9K | 17,992 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | M Exercise deriv | 2024-11-07 | 2024-11-12 | 10,000 | — | $0 | 27,947 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | S Sale | 2024-11-07 | 2024-11-12 | 1,868 | $54.41 | $101.6K | 7,992 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | M Exercise | 2024-11-07 | 2024-11-12 | 10,000 | $25.99 | $259.9K | 17,992 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | S Sale | 2024-11-07 | 2024-11-12 | 8,132 | $53.32 | $433.6K | 9,860 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise deriv | 2024-10-08 | 2024-10-10 | 4,106 | — | $0 | 12,322 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise deriv | 2024-10-08 | 2024-10-10 | 6,314 | — | $0 | 69,428 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2024-10-08 | 2024-10-10 | 10,420 | $28.17 | $293.5K | 22,341 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise | 2024-10-08 | 2024-10-10 | 4,106 | $5.52 | $22.7K | 32,761 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise | 2024-10-08 | 2024-10-10 | 6,314 | $19.68 | $124.3K | 28,655 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | M Exercise deriv | 2024-08-11 | 2024-08-13 | 2,302 | — | $0 | 2,302 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | M Exercise | 2024-08-11 | 2024-08-13 | 2,302 | — | $0 | 7,992 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | A Award deriv | 2024-06-20 | 2024-06-24 | 11,774 | — | $0 | 11,774 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | A Award deriv | 2024-06-20 | 2024-06-24 | 2,120 | — | $0 | 2,120 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | M Exercise deriv | 2024-06-13 | 2024-06-17 | 3,388 | — | $0 | 0 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | M Exercise | 2024-06-13 | 2024-06-17 | 3,388 | — | $0 | 5,690 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise deriv | 2024-04-11 | 2024-04-12 | 48,820 | — | $0 | 0 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise deriv | 2024-04-11 | 2024-04-12 | 4,580 | — | $0 | 75,742 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise | 2024-04-11 | 2024-04-12 | 4,580 | $19.68 | $90.1K | 75,741 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2024-04-11 | 2024-04-12 | 30,300 | $23.14 | $701.1K | 45,441 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2024-04-11 | 2024-04-12 | 20,032 | $25.00 | $500.8K | 25,409 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2024-04-11 | 2024-04-12 | 3,068 | $25.21 | $77.3K | 22,341 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise | 2024-04-11 | 2024-04-12 | 48,820 | $12.60 | $615.1K | 71,161 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise deriv | 2024-04-10 | 2024-04-12 | 13,600 | — | $0 | 48,820 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2024-04-10 | 2024-04-12 | 13,600 | $21.01 | $285.7K | 22,341 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise | 2024-04-10 | 2024-04-12 | 13,600 | $12.60 | $171.4K | 35,941 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise deriv | 2024-04-04 | 2024-04-08 | 3,485 | — | $0 | 62,420 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise | 2024-04-04 | 2024-04-08 | 3,485 | $12.60 | $43.9K | 25,826 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2024-04-04 | 2024-04-08 | 3,485 | $19.15 | $66.7K | 22,341 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise deriv | 2024-04-01 | 2024-04-03 | 3,143 | — | $0 | 16,428 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise deriv | 2024-04-01 | 2024-04-03 | 94 | — | $0 | 65,905 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise | 2024-04-01 | 2024-04-03 | 3,143 | $5.52 | $17.3K | 25,578 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2024-04-01 | 2024-04-03 | 3,237 | $19.08 | $61.8K | 22,341 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise | 2024-04-01 | 2024-04-03 | 94 | $12.60 | $1.2K | 22,435 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise deriv | 2024-03-20 | 2024-03-22 | 13,278 | — | $0 | 19,571 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2024-03-20 | 2024-03-22 | 13,278 | $19.16 | $254.4K | 22,341 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise | 2024-03-20 | 2024-03-22 | 13,278 | $5.52 | $73.3K | 35,619 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | A Award deriv | 2024-02-13 | 2024-02-15 | 16,835 | — | $0 | 16,835 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | A Award deriv | 2024-02-13 | 2024-02-20 | 23,364 | — | $0 | 23,364 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | M Exercise deriv | 2023-08-11 | 2023-08-15 | 2,302 | — | $0 | 4,604 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | M Exercise | 2023-08-11 | 2023-08-15 | 2,302 | — | $0 | 2,302 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | A Award deriv | 2023-06-13 | 2023-06-15 | 18,958 | — | $0 | 18,958 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | A Award deriv | 2023-06-13 | 2023-06-15 | 3,388 | — | $0 | 3,388 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | A Award deriv | 2023-02-23 | 2023-04-06 | 27,567 | — | $0 | 27,567 | SEC↗ |
| IMRA IMARA Inc. | S Sale | 2023-02-22 | 2023-02-22 | 32,861 | $4.66 | $153.1K | 87,835 | SEC↗ |
| IMRA IMARA Inc. | S Sale | 2023-01-30 | 2023-02-01 | 11,313 | $3.91 | $44.2K | 120,696 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | A Award deriv | 2022-08-11 | 2022-08-15 | 37,947 | — | $0 | 37,947 | SEC↗ |
| AGIO AGIOS PHARMACEUTICALS, INC | A Award deriv | 2022-08-11 | 2022-08-15 | 6,906 | — | $0 | 6,906 | SEC↗ |
| IMRA IMARA Inc. | A Award deriv | 2022-01-28 | 2022-02-01 | 131,400 | — | $0 | 131,400 | SEC↗ |
| IMRA IMARA Inc. | A Award | 2022-01-28 | 2022-02-01 | 131,400 | — | $0 | 137,009 | SEC↗ |
| IMRA IMARA Inc. | A Award deriv | 2021-01-28 | 2021-02-01 | 133,350 | — | $0 | 133,350 | SEC↗ |
| IMRA IMARA Inc. | M Exercise deriv | 2020-12-17 | 2020-12-21 | 4,999 | — | $0 | 263,999 | SEC↗ |
| IMRA IMARA Inc. | M Exercise | 2020-12-17 | 2020-12-21 | 4,999 | $3.15 | $15.7K | 4,999 | SEC↗ |
| IMRA IMARA Inc. | S Sale | 2020-12-17 | 2020-12-21 | 4,999 | $25.00 | $125.0K | 0 | SEC↗ |
| IMRA IMARA Inc. | M Exercise deriv | 2020-12-14 | 2020-12-16 | 1 | — | $0 | 268,998 | SEC↗ |
| IMRA IMARA Inc. | M Exercise | 2020-12-14 | 2020-12-16 | 1 | $3.15 | $3 | 1 | SEC↗ |
| IMRA IMARA Inc. | S Sale | 2020-12-14 | 2020-12-16 | 1 | $25.00 | $25 | 0 | SEC↗ |